TWi successfully launches generic Cyclobenzaprine HCL ER Capsules in TWi label

March 1, 2019. TWi Pharmaceuticals, Inc. (“TWi”) (Stock Ticker: 4180.TT) today announced the official launch of Cyclobenzaprine HCL ER Capsules (equivalent to Amrix®).

Cyclobenzaprine HCL ER Capsules are indicated as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions. According to IQVIA data, the total sales of Cyclobenzaprine HCL ER Capsules/Amrix® in the US were approximately US $47.5 million for the 12 months ended January 2019.

About TWi Pharmaceuticals, Inc.
TWi Pharmaceuticals, Inc. is a leading specialty pharmaceutical company based in Taipei, Taiwan, focusing on the development of high barrier to entry generic prescription products ranging from oral controlled release dosage forms to novel drug delivery systems including the utilization of nanoparticles, transdermal, and polymeric oral delivery systems. Leveraging its internal research and development capabilities, together with operational flexibility, process development, manufacturing and regulatory expertise, TWi Pharmaceuticals concentrates on products and technologies that present significant barriers to entry or offer unparalleled market opportunities in the United States. For more information on TWi Pharmaceuticals and its fully owned US subsidiary, TWi Pharmaceuticals USA, Inc., please visit www.twipharma.com

Contact :
Angela Luan
Finance/ Investor Relations
Email: angela.luan@twipharma.com